VERTEX PHARMACEUTICALS INC / MA (VRTX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.47%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 5.47% | Share-based compensation / revenue. Period ending 2026-06-30. $689.10M ÷ $12.59B × 100 ≈ 5.47% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 12.59B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 689.10M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 4.78B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $12.59B | $689.10M | $4.78B | (m) | (m) | 5.47% | (m) | (m) |
| 2026-03-31 | (m) | $12.22B | $686.20M | $4.68B | (m) | (m) | 5.62% | (m) | (m) |
| 2025-12-31 | (m) | $12.00B | $685.90M | $4.17B | (m) | (m) | 5.72% | (m) | (m) |
| 2025-09-30 | (m) | $11.72B | $696.10M | $3.99B | (m) | (m) | 5.94% | (m) | (m) |
| 2025-06-30 | (m) | $11.42B | $685.80M | $3.92B | (m) | (m) | 6.01% | (m) | (m) |
| 2025-03-31 | (m) | $11.10B | $672.70M | $-742.30M | (m) | (m) | 6.06% | (m) | (m) |
| 2024-12-31 | (m) | $11.02B | $698.50M | $-232.90M | (m) | (m) | 6.34% | (m) | (m) |
| 2024-09-30 | (m) | $10.63B | $739.30M | $-270.40M | (m) | (m) | 6.96% | (m) | (m) |
| 2024-06-30 | (m) | $10.34B | $685.60M | $-348.60M | (m) | (m) | 6.63% | (m) | (m) |
| 2024-03-31 | (m) | $10.19B | $650.70M | $4.19B | (m) | (m) | 6.39% | (m) | (m) |
| 2023-12-31 | (m) | $9.87B | $581.20M | $3.83B | (m) | (m) | 5.89% | (m) | (m) |
| 2023-09-30 | (m) | $9.65B | $484.10M | $3.88B | (m) | (m) | 5.01% | (m) | (m) |
| 2023-06-30 | (m) | $9.51B | $488.80M | $3.97B | (m) | (m) | 5.14% | (m) | (m) |
| 2023-03-31 | (m) | $9.21B | $483.40M | $4.05B | (m) | (m) | 5.25% | (m) | (m) |
| 2022-12-31 | (m) | $8.93B | $491.30M | $4.31B | (m) | (m) | 5.50% | (m) | (m) |
| 2022-09-30 | (m) | $8.70B | $498.40M | $4.15B | (m) | (m) | 5.73% | (m) | (m) |
| 2022-06-30 | (m) | $8.35B | $465.80M | $4.08B | (m) | (m) | 5.58% | (m) | (m) |
| 2022-03-31 | $3.20B | $7.95B | $456.50M | $2.94B | (m) | 40.24% | 5.74% | (m) | (m) |
| 2021-12-31 | $3.05B | $7.57B | $441.40M | $2.78B | (m) | 40.28% | 5.83% | (m) | (m) |
| 2021-09-30 | $2.82B | $7.13B | $419.82M | $2.65B | (m) | 39.60% | 5.89% | (m) | (m) |
| 2021-06-30 | $2.82B | $6.68B | $416.36M | $2.27B | (m) | 42.24% | 6.23% | (m) | (m) |
| 2021-03-31 | $1.84B | $6.41B | $428.93M | $3.02B | (m) | 28.64% | 6.69% | (m) | (m) |
| 2020-12-31 | $1.83B | $6.21B | $429.46M | $2.86B | $58.15M | 29.48% | 6.92% | 49.12× | Reported |
| 2020-09-30 | $1.84B | $5.99B | $424.02M | $2.66B | (m) | 30.76% | 7.08% | (m) | (m) |
| 2020-06-30 | $1.91B | $5.40B | $409.91M | $2.09B | (m) | 35.27% | 7.59% | (m) | (m) |
| 2020-03-31 | $1.86B | $4.82B | $382.40M | $1.64B | (m) | 38.67% | 7.93% | (m) | (m) |
| 2019-12-31 | $1.75B | $4.16B | $360.49M | $1.20B | $58.50M | 42.15% | 8.66% | 20.47× | Reported |
| 2019-09-30 | $1.71B | $3.62B | $347.84M | $773.82M | (m) | 47.31% | 9.61% | (m) | (m) |
| 2019-06-30 | $1.49B | $3.45B | $347.95M | $880.14M | (m) | 43.05% | 10.07% | (m) | (m) |
| 2019-03-31 | $1.45B | $3.27B | $340.70M | $783.06M | (m) | 44.27% | 10.43% | (m) | (m) |
| 2018-12-31 | $1.42B | $3.05B | $325.05M | $635.15M | (m) | 46.48% | 10.67% | (m) | (m) |
| 2018-09-30 | $1.29B | $2.83B | $319.85M | $633.16M | (m) | 45.43% | 11.31% | (m) | (m) |
| 2018-06-30 | $1.41B | $2.62B | $308.77M | $101.47M | (m) | 53.75% | 11.77% | (m) | (m) |
| 2018-03-31 | $1.36B | $2.41B | $299.43M | $-18.70M | (m) | 56.39% | 12.40% | (m) | (m) |
| 2017-12-31 | $1.32B | $2.49B | $290.74M | $123.24M | (m) | 53.23% | 11.68% | (m) | (m) |
| 2017-09-30 | $1.27B | $2.30B | $274.42M | $37.15M | (m) | 55.16% | 11.95% | (m) | (m) |
| 2017-06-30 | $1.08B | $2.13B | $261.86M | $344.46M | (m) | 50.85% | 12.29% | (m) | (m) |
| 2017-03-31 | $1.07B | $2.02B | $251.22M | $295.11M | (m) | 52.77% | 12.44% | (m) | (m) |
| 2016-12-31 | $1.05B | $1.70B | $237.71M | $9.94M | (m) | 61.55% | 13.96% | (m) | (m) |
| 2016-09-30 | $1.11B | $1.66B | $223.27M | $-83.41M | (m) | 66.78% | 13.44% | (m) | (m) |
| 2016-06-30 | $1.08B | $1.56B | $227.79M | $-134.71M | (m) | 69.56% | 14.63% | (m) | (m) |
| 2016-03-31 | $1.04B | $1.29B | $229.11M | $-309.22M | (m) | 80.21% | 17.73% | (m) | (m) |
| 2015-12-31 | $995.92M | $1.03B | $231.03M | $-466.88M | (m) | 96.47% | 22.38% | (m) | (m) |
| 2015-09-30 | $887.20M | $758.96M | $228.76M | $-566.80M | (m) | 116.90% | 30.14% | (m) | (m) |
| 2015-06-30 | $831.86M | $628.13M | $209.16M | $-638.98M | (m) | 132.43% | 33.30% | (m) | (m) |
| 2015-03-31 | $832.49M | $600.47M | $188.35M | $-648.36M | (m) | 138.64% | 31.37% | (m) | (m) |
| 2014-12-31 | $855.51M | $580.41M | $177.54M | $-692.41M | (m) | 147.40% | 30.59% | (m) | (m) |
| 2014-09-30 | $929.19M | $787.02M | $158.53M | $-842.51M | (m) | 118.06% | 20.14% | (m) | (m) |
| 2014-06-30 | $941.98M | $829.73M | $143.70M | $-805.45M | (m) | 113.53% | 17.32% | (m) | (m) |
| 2014-03-31 | $939.65M | $1.00B | $142.61M | $-681.55M | (m) | 93.77% | 14.23% | (m) | (m) |
| 2013-12-31 | $918.78M | $1.21B | $127.30M | $-903.45M | (m) | 75.81% | 10.50% | (m) | (m) |
| 2013-09-30 | $882.28M | $1.19B | $131.57M | $-706.76M | (m) | 73.84% | 11.01% | (m) | (m) |
| 2013-06-30 | $853.82M | $1.31B | $127.84M | $-573.77M | (m) | 65.22% | 9.77% | (m) | (m) |
| 2013-03-31 | $827.91M | $1.42B | $117.87M | $-527.61M | (m) | 58.44% | 8.32% | (m) | (m) |
| 2012-12-31 | $806.18M | $1.53B | $114.28M | $2.33M | $16.65M | 52.79% | 7.48% | 0.14× | Reported |
| 2012-09-30 | $779.51M | $1.76B | $115.70M | $303.71M | $25.29M | 44.38% | 6.59% | 12.01× | Reported |
| 2012-06-30 | $768.40M | $2.08B | $117.53M | $520.49M | $27.79M | 36.95% | 5.65% | 18.73× | Reported |
| 2012-03-31 | $745.47M | $1.78B | $118.03M | $365.37M | $30.56M | 41.98% | 6.65% | 11.96× | Reported |
| 2011-12-31 | $707.71M | $1.41B | $118.23M | $113.82M | $38.45M | 50.17% | 8.38% | 2.96× | Reported |
| 2011-09-30 | $690.16M | $912.81M | $112.75M | $-276.72M | $33.71M | 75.61% | 12.35% | -8.21× | Reported |
| 2011-06-30 | $671.54M | $277.40M | $107.10M | $-692.01M | $30.60M | 242.08% | 38.61% | -22.61× | Reported |
| 2011-03-31 | $653.02M | $194.60M | $99.67M | $-695.69M | $27.32M | 335.56% | 51.22% | -25.46× | Reported |
| 2010-12-31 | $637.42M | $143.37M | $91.12M | $-696.08M | $19.27M | 444.60% | 63.56% | -36.11× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $550.27M | $101.89M | $86.72M | $-614.01M | $13.19M | 540.07% | 85.11% | -46.54× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $516.91M | $175.50M | $57.98M | $-462.71M | $13.47M | 294.53% | 33.04% | -34.35× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |